Abstract:Identifying and refining clinically significant patient stratification is a critical step toward realizing the promise of precision medicine in asthma. Several peripheral blood hallmarks, including total peripheral blood eosinophil count (BEC) and immunoglobulin E (IgE) levels, are routinely used in asthma clinical practice for endotype classification and predicting response to state-of-the-art targeted biologic drugs. However, these biomarkers appear ineffective in predicting treatment outcomes in some patients, and they differ in distribution between racially and ethnically diverse populations, potentially compromising medical care and hindering health equity due to biases in drug eligibility. Here, we propose constructing an unbiased patient stratification score based on DNA methylation (DNAm) and utilizing it to refine the efficacy of hallmark biomarkers for predicting drug response. We developed Phenotype Aware Component Analysis (PACA), a novel contrastive machine-learning method for learning combinations of DNAm sites reflecting biomedically meaningful patient stratifications. Leveraging whole-blood DNAm from Latino (discovery; n=1,016) and African American (replication; n=756) pediatric asthma case-control cohorts, we applied PACA to refine the prediction of bronchodilator response (BDR) to the short-acting β2-agonist albuterol, the most used drug to treat acute bronchospasm worldwide. While BEC and IgE correlate with BDR in the general patient population, our PACA-derived DNAm score renders these biomarkers predictive of drug response only in patients with high DNAm scores. BEC correlates with BDR in patients with upper-quartile DNAm scores (OR 1.12; 95% CI [1.04, 1.22]; P=7.9 e-4) but not in patients with lower-quartile scores (OR 1.05; 95% CI [0.95, 1.17]; P=0.21); and IgE correlates with BDR in above-median (OR for response 1.42; 95% CI [1.24, 1.63]; P=3.9e-7) but not in below-median patients (OR 1.05; 95% CI [0.92, 1.2]; P=0.57). These results hold within the commonly recognized type 2 (T2)-high asthma endotype but not in T2-low patients, suggesting that our DNAm score primarily represents an unknown variation of T2 asthma. Among T2-high patients with high DNAm scores, elevated BEC or IgE also corresponds to baseline clinical presentation that is known to benefit more from biologic treatment, including higher exacerbation scores, higher allergen sensitization, lower BMI, more recent oral corticosteroids prescription, and lower lung function. Our findings suggest that BEC and IgE, the traditional asthma biomarkers of T2-high asthma, are poor biomarkers for millions worldwide. Revisiting existing drug eligibility criteria relying on these biomarkers in asthma medical care may enhance precision and equity in treatment.

High-dimensional profiling clusters asthma severity by lymphoid and non-lymphoid status

A Strategy for High-Dimensional Multivariable Analysis Classifies Childhood Asthma Phenotypes from Genetic, Immunological, and Environmental Factors

Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases

Lung function, airway and peripheral basophils and eosinophils are associated with molecular pharmacogenomic endotypes of steroid response in severe asthma

Identification and validation of three potential biomarkers and immune microenvironment for in severe asthma in microarray and single-cell datasets

Deciphering the Immune Subtypes and Signature Genes: A Novel Approach Towards Diagnosing and Prognosticating Severe Asthma through Interpretable Machine Learning

Single-cell transcriptomic analysis reveals key immune cell phenotypes in the lungs of patients with asthma exacerbation

A cellular census of human lungs identifies novel cell states in health and in asthma

Radiomultiomics: quantitative CT clusters of severe asthma associated with multi-omics

A cellular census of healthy lung and asthmatic airway wall identifies novel cell states in health and disease

High-Dimensional Mass Cytometry Reveals Emphysema-associated Changes in the Pulmonary Immune System

Endotypes of severe neutrophilic and eosinophilic asthma from multi-omics integration of U-BIOPRED sputum samples

Clusters based on immune markers in a Lithuanian asthma cohort study

Epigenetic patient stratification via contrastive machine learning refines hallmark biomarkers in minoritized children with asthma

High-dimensional tissue profiling of immune cell responses in chronic lung allograft dysfunction

Machine Learning and Bioinformatics Approaches to Identify the Candidate Biomarkers in Severe Asthma

Pathological ILC2 in Peripheral Blood Acts As an Indicator for the Assessment of Asthma Control in Clinics

Protein–Protein interactive networks identified in bronchoalveolar lavage of severe compared to nonsevere asthma

Clinical Significance of Combined Detection of CCL22 and IL‐1 as Potential New Bronchial Inflammatory Mediators in Children's Asthma

Proteomic profiling of bronchoalveolar lavage fluid uncovers protein clusters linked to survival in idiopathic forms of interstitial lung disease

Single-cell RNA sequencing unraveled the expression heterogeneity of hematopoietic stem and progenitor cells and lymphoid cell development dysregulation in childhood asthma